Compile Data Set for Download or QSAR
maximum 50k data
Found 66 Enz. Inhib. hit(s) with all data for entry = 129
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50444038(CHEMBL3092563 | US9669035, B-5)
Affinity DataIC50:  1.40nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425123(CHEMBL2313234 | US9669035, B-3)
Affinity DataIC50:  2.30nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026827(CHEMBL3331516 | US9669035, B-6)
Affinity DataIC50:  4.80nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026829(CHEMBL3331514 | US9669035, B-7)
Affinity DataIC50:  6.20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026828(CHEMBL3331515 | US9669035, B-8)
Affinity DataIC50:  6.5nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026821(CHEMBL3331521 | US11419874, Example 10 | US9669035...)
Affinity DataIC50:  7.40nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026826(CHEMBL3331517 | US11419874, Example 9 | US9669035,...)
Affinity DataIC50:  7.80nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179970(US9669035, B-9)
Affinity DataIC50:  9.5nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026820(CHEMBL3331513 | US9669035, B-10)
Affinity DataIC50:  10nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179972(US9669035, B-11)
Affinity DataIC50:  11nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026825(CHEMBL3331518 | US9669035, B-12)
Affinity DataIC50:  12nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026821(CHEMBL3331521 | US11419874, Example 10 | US9669035...)
Affinity DataIC50:  13nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50444038(CHEMBL3092563 | US9669035, B-5)
Affinity DataIC50:  14nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181755(US9669035, B-25)
Affinity DataIC50:  18nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425125(CHEMBL2313232 | US9669035, B-4)
Affinity DataIC50:  20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425124(CHEMBL2313233 | US9669035, B-13)
Affinity DataIC50:  20nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179977(US9669035, B-14)
Affinity DataIC50:  21nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181763(US9669035, B-26)
Affinity DataIC50:  22nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179978(US9669035, B-15)
Affinity DataIC50:  22nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026824(CHEMBL3331519 | US9669035, B-16)
Affinity DataIC50:  30nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425123(CHEMBL2313234 | US9669035, B-3)
Affinity DataIC50:  34nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179980(US9669035, B-17)
Affinity DataIC50:  35nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179981(US9669035, B-18)
Affinity DataIC50:  36nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181676(US9669035, B-22a)
Affinity DataIC50:  44nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179983(US9669035, B-20)
Affinity DataIC50:  45nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179982(US9669035, B-19)
Affinity DataIC50:  46nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181673(US9669035, B-21)
Affinity DataIC50:  49nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181678(US9669035, B-23)
Affinity DataIC50:  52nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182096(US9669035, B-27)
Affinity DataIC50:  74nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179970(US9669035, B-9)
Affinity DataIC50:  85nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182226(US9669035, B-28)
Affinity DataIC50:  91nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026820(CHEMBL3331513 | US9669035, B-10)
Affinity DataIC50:  100nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425124(CHEMBL2313233 | US9669035, B-13)
Affinity DataIC50:  110nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182234(US9669035, B-29)
Affinity DataIC50:  120nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182294(US9669035, B-30)
Affinity DataIC50:  130nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50425125(CHEMBL2313232 | US9669035, B-4)
Affinity DataIC50:  160nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181713(US9669035, B-24)
Affinity DataIC50:  190nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026829(CHEMBL3331514 | US9669035, B-7)
Affinity DataIC50:  260nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026825(CHEMBL3331518 | US9669035, B-12)
Affinity DataIC50:  270nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026828(CHEMBL3331515 | US9669035, B-8)
Affinity DataIC50:  320nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179981(US9669035, B-18)
Affinity DataIC50:  320nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182857(US9669035, B-31)
Affinity DataIC50:  330nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182858(US9669035, B-32)
Affinity DataIC50:  350nMpH: 7.8 T: 2°CAssay Description:Human recombinant PDE2A (hPDE2A) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of inf...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM181676(US9669035, B-22a)
Affinity DataIC50:  910nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM182857(US9669035, B-31)
Affinity DataIC50:  1.40E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179978(US9669035, B-15)
Affinity DataIC50:  1.50E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179980(US9669035, B-17)
Affinity DataIC50:  1.60E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026826(CHEMBL3331517 | US11419874, Example 9 | US9669035,...)
Affinity DataIC50:  1.60E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM179977(US9669035, B-14)
Affinity DataIC50:  1.80E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Rattus norvegicus (rat))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM50026827(CHEMBL3331516 | US9669035, B-6)
Affinity DataIC50:  1.90E+3nMpH: 7.8 T: 2°CAssay Description:Rat recombinant PDE10A (rPDE10A2) was expressed in Sf9 cells using a recombinant rPDE10A baculovirus construct. Cells were harvested after 48 h of in...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 66 total ) | Next | Last >>
Jump to: